关注资本市场的趋势与发展 以下文章来源于信风TradeWind ，作者郑敏芳 信风TradeWind . 作者 | 郑敏芳 起因正是新氧自营诊所复配的童颜针"艾维岚"产品（又称"奇迹童颜"）售价仅为5999元， 为市场公价的1/3，这引发了艾维岚品牌方长春圣博玛生物材料有限公司（下称"圣博 玛"）的不满。 笔者注意到，新氧早在2023年就与上游医美材料商东方妍美（成都）生物技术股份有限公 司（下称"东方妍美"）达成战略合作，后者将尚未上市的童颜针XH301等多款产品的国内 商业化权利独家授权给新氧。 随着此番东方妍美踏上港股IPO之路，其XH301的上市进展情况得以披露。 作为东方妍美的核心产品，XH301预计今年下半年完成国内上市审评，欧盟上市注册进程 则处于提交阶段。 来源 | 信风TradeWind 圣博玛发文指出，不对新氧诊所销售的艾维岚提供正品保证责任；新氧则强调旗下产品均 为正品，指责圣博玛的说法是"无端抹黑"。 导 语： 圣博玛发文指出，不对新氧诊所销售的艾维岚提供正品保证责任；新氧则强调旗下 产品均为正品，指责圣博玛的说法是"无端抹黑"。 童颜针价格战一触即发。 6月19日，新氧CEO金星发文 ...

Core Viewpoint - New Oxygen Technology (NASDAQ: SY) is facing a dual challenge of declining revenue and increasing losses, with significant fluctuations in performance over recent years [1][2] Financial Performance - In 2024, New Oxygen's total revenue is projected to be 1.467 billion yuan, a year-on-year decrease of 2.09% - Gross profit is expected to be 899 million yuan, down 5.72% year-on-year - Net loss is anticipated to reach 587 million yuan, with a net loss attributable to New Oxygen International of 590 million yuan [1] Recent Quarterly Results - In Q1 2025, New Oxygen's total revenue was 297 million yuan, a year-on-year decline of 6.6% - Net loss expanded to 33.1 million yuan, a 56.13% increase compared to the 21.2 million yuan loss in the same period of 2024 - Gross margin decreased from 63% in Q1 2024 to 49% in Q1 2025, indicating a significant decline in profitability [1] Business Challenges - The primary reason for New Oxygen's negative revenue growth is the severe impact on its traditional core business, "Information and Appointment Services" - This segment, which accounted for 100% of revenue in 2020, saw revenue drop from 1.151 billion yuan in 2023 to 929 million yuan in 2024, reducing its share to 63.4% - Emerging platforms like Douyin and Xiaohongshu are diverting advertising budgets from medical beauty institutions, while comprehensive platforms like Alibaba Health and Meituan are capturing market share due to their traffic advantages, leading to a significant reduction in the number of subscribed institutions [2]

Core Insights - The 2025 New Fortune 500 Rich List highlights AI as a major driving force for wealth creation among the top entrepreneurs [1][3] - The geographical focus of China's economy is shifting, with a notable increase in wealth concentration in Zhejiang, particularly Hangzhou, while Guangdong's representation has decreased significantly [2][10] Group 1: Wealth Distribution and Rankings - The total market value of the 500 entrepreneurs on the list is 13.7 trillion yuan, an 11% increase year-on-year, with an average market value of 27.38 billion yuan per individual [3] - Zhang Yiming, founder of ByteDance, tops the list with a valuation of 481.57 billion yuan, marking a significant rise from 12 billion yuan seven years ago [4] - ByteDance's revenue reached 155 billion USD in 2024, a 29% increase, with a net profit of 33 billion USD, making it the leading internet technology company in China [5] Group 2: Industry Trends and Emerging Entrepreneurs - The TMT (Technology, Media, and Telecommunications) sector leads the list with 110 entrepreneurs, a significant increase of 22 from the previous year, contributing 3.34 trillion yuan, or 25% of the total wealth on the list [7] - The semiconductor industry is identified as a key wealth generator within the TMT sector, with notable figures like Chen Tian Shi of Cambrian holding a market value of 78.6 billion yuan, a 370% increase [7] - New entrants in emerging fields such as humanoid robotics and industrial robotics are also highlighted, with notable figures like Wang Xingxing of Yushutech making their debut on the list [8] Group 3: Regional Wealth Dynamics - Guangdong remains the province with the highest number of listed entrepreneurs, though its count has dropped from 112 in 2021 to 96 in 2025, with total wealth decreasing from 4.5 trillion yuan to 3 trillion yuan [10] - Zhejiang has seen a rise in representation, with 76 entrepreneurs, surpassing Beijing, which has seen a decline from 83 to 70 [13] - The rise of the Yangtze River Delta region is evident, with Shanghai and Jiangsu also increasing their number of listed entrepreneurs, driven by sectors like semiconductors and consumer spending [13][14]

Group 1 - The stock price of New Oxygen surged by 41.88% on Monday, reaching $1.66 per share and a market capitalization of $166 million, following a previous increase of 15.84% [1] - New Oxygen's stock had been underperforming since its NASDAQ debut in May 2019, where it initially rose by 31.88% to a market cap of approximately $1.823 billion [1] - Analysts attribute the recent stock surge to strong growth in the company's chain business, while advertising and upstream businesses remain undervalued [1] Group 2 - Founded in 2013, New Oxygen initially focused on an internet medical beauty platform, achieving rapid revenue growth from 49 million RMB in 2016 to 617 million RMB in 2018, with a compound annual growth rate of 254.85% [2] - The company has faced significant challenges in recent years due to competition from platforms like Alibaba Health and Meituan, as well as content e-commerce platforms like Douyin and Xiaohongshu [2] - New Oxygen plans to launch a new light medical beauty chain brand "New Oxygen Youth Clinic" in November 2024, aiming to reduce costs through centralized procurement and improve service efficiency [2] Group 3 - As of March 31, 2025, New Oxygen operates 23 medical beauty centers across nine major cities in China, with 18 centers achieving positive monthly cash flow [2] - The company reported a significant increase in quarterly write-off projects, exceeding 92,900, and a growth in quarterly paid users by 874% to over 45,500 [2] - Active user numbers surpassed 75,700, reflecting an 846% year-on-year increase, indicating enhanced user engagement [2] Group 4 - New Oxygen has recently been involved in disputes regarding its "Miracle Youth" project, which offers a product at a significantly lower price than the official price set by the manufacturer [3] - The company defends its product authenticity and compliance, while accusing competitors of unfair practices [3]

Core Insights - The medical beauty industry, particularly the hyaluronic acid market, is experiencing rapid growth, with major players like Aimeike, Huaxi Biological, and Haohai Biological achieving significant revenue increases and maintaining high gross profit margins, although there are signs of potential declines in these margins due to increased competition and market saturation [1][2][7][8] Group 1: Sales and Profitability - The overall gross profit margin for the leading companies in the hyaluronic acid market remains above 70%, with Aimeike reaching a peak margin of 95% by 2024, while Huaxi Biological and Haohai Biological are projected to see declines in their margins to 74.07% and 69.52% respectively by 2024 [1] - Aimeike's injection products contribute nearly 98% of its total revenue in 2024, with sales of solution-type injections reaching 1.744 billion and gel-type injections at 1.216 billion [8] Group 2: Business Development Strategies - Haohai Biological has pursued a strategy of mergers and acquisitions since 2007, completing nearly 20 transactions to expand its business into various sectors, including ophthalmology and medical aesthetics, with medical beauty and wound care projected to generate 1.195 billion in revenue in 2024, reflecting a 13.06% year-on-year growth [2][5] - Huaxi Biological has diversified its business model since 2012, moving from raw material supply to include medical, functional skincare, and functional food sectors, with functional skincare sales expected to reach 2.569 billion in 2024, accounting for 47.84% of total revenue [7]

Group 1 - The core issue revolves around the dispute between two major players in the medical beauty industry, Juzi Biotechnology and Huaxi Biotechnology, regarding recombinant collagen products [2] - Juzi Biotechnology acknowledged limitations in its current quality standards, testing methods, and labeling, which are not fully aligned with the industry's evolving high standards and technological advancements [2][7] - Following the announcement, Juzi Biotechnology's stock price surged over 7% on June 24 [3] Group 2 - Juzi Biotechnology outlined three future initiatives: collaborating with research institutions to enhance testing methods for recombinant collagen in cosmetics, gradually disclosing key technical parameters and quality control data, and actively participating in the formulation of national and industry standards for recombinant collagen [7] - Huaxi Biotechnology previously addressed concerns about the lack of relevant testing standards in the recombinant collagen sector, emphasizing the misuse of the term "collagen" and the need for clear scientific conclusions to avoid misleading the market and consumers [10]

6 月 23 日晚，巨子生物在官方微信公众号发布关于重组胶原蛋白产品有关问题的说明，明晰 了自查结果和下一步措施。 巨子生物承认： " 我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其 局限性，难以完全适配行业发展与技术进步的高标准和高要求。 " 【导读】巨子生物回应重组胶原蛋白产品问题 中国基金报记者 赵心怡 两大医美巨头 —— 巨子生物和华熙生物之间的纷争迎来 " 最终章 " 。（此前详情可参考报 道《 价值研究所｜撕扯、炒作？美妆巨头成分 " 罗生门 " 》） 6 月 24 日开盘，巨子生物股价一度大涨超 7% 。 巨子生物：检测标准和方法存在局限性 从现有行业标准来看，发布和实施日期基本集中在近 5 年，目前最新的一版是 2025 年发布 的医药行业标准 YY/T 1947-2025 《重组胶原蛋白敷料》，将于 2026 年 3 月实施。 巨子生物表示： " 随着重组胶原蛋白产业的快速发展，以及消费者对产品质量要求的日益增 长，我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其局限性，难以 完全适配行业发展与技术进步的高标准和高要求，需要不断优化迭代。 " 对于未来发展， ...

近年来，伴随社交媒体裂变式扩散与消费升级，"颜值经济"呈爆发式增长。其中，改善塑形项目因其微 创和即时见效越来越受到青睐。 据美团数据统计，2025年，中国医美市场规模已突破千亿大关，年服务人次超过2600万，轻医美渗透率 从2019年的边缘角色跃升为行业主流。 然而，在行业高速发展的背后，市场信息杂乱、机构过度营销、效果无法保障等常见痛点，还是让消费 者从决策到售后的每个环节都充满了担忧。 "都说医美行业水很深，就算是大医院、名机构，也有很多失败的案例和不靠谱的医生。"一位经常做医 美项目的求美者小婷告诉观察者网，其每次在做新项目前都会在各大平台搜索相关医院和医生的过往案 例，但触目惊心的维权帖总让她陷入选择焦虑。 更令人担忧的是，就连业内人士也对行业现状心存芥蒂。前医美从业者琦琦坦言："可能是因为曾在医 美机构工作过，知道里面的医生技术参差不齐，所以更不敢轻易尝试。如果要做的话，更倾向于找行业 内朋友进行推荐。" 当颜值焦虑催生千亿市场，而求美之心却遭遇信任危机时，不禁要问：这个光鲜亮丽的行业何时才能建 立起让消费者放心的透明机制？从医疗机构到执业医师，从第三方平台到行业联盟，又能做些什么让求 美者真正实 ...

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The demand for photon rejuvenation services is diversifying, leading to personalized and technology-integrated innovations [4][28] - The market for photon rejuvenation services in China is expected to grow significantly, from 2.7 billion to 4.8 billion yuan between 2023 and 2027 [7] - The industry is transitioning from a phase of rapid expansion to one of standardized operations due to increased regulatory scrutiny [27] Market Background - Photon rejuvenation is a non-surgical aesthetic service that utilizes pulsed light energy to treat skin issues caused by sun exposure [5] - The technology has evolved since its introduction in the late 1990s, with significant advancements in domestic equipment development [6] Market Status - The market size for photon rejuvenation services in China grew from 820 million yuan in 2017 to 2.42 billion yuan in 2022, with a projected increase to 4.8 billion yuan by 2027 [7] - The supply side of the market is highly active, with many local companies enhancing their capabilities through R&D and acquisitions [8] - Demand remains strong due to the non-invasive nature of the service, appealing to a diverse consumer base [9][10] Market Competition - The competitive landscape is divided into three tiers, with leading brands like Jingfu and Meilai dominating the market [14][17] - The evaluation of brands is based on sales volume, depth of market engagement, and the variety of services offered [11][12][13] - The report recommends ten leading brands in the photon rejuvenation sector, highlighting their unique strengths and market positions [16][17][18][19][20][21][22][23][24][25][26] Development Trends - The industry is moving towards high-quality development driven by regulatory compliance and technological standardization [27] - Consumer demand is evolving towards personalized solutions, with AI technology enhancing treatment customization [28] - The trend of chain operations and digitalization is reshaping the competitive landscape, favoring larger, more efficient players [29]

Core Viewpoint - The company is facing a dual challenge of declining revenue and increasing losses, primarily due to the significant downturn in its traditional core business of "information and appointment services" [2][6][11]. Revenue and Profitability - In Q1 2025, the company's total revenue was 297 million RMB, a year-on-year decline of 6.6%, with net losses expanding to 33.1 million RMB, a 56.13% increase from the same period in 2024 [3]. - The company's revenue experienced significant fluctuations in recent years: 1) 2021 revenue reached 1.692 billion RMB, up 30.7% due to the recovery of the medical beauty industry and acquisitions; 2) 2022 saw a sharp decline of 25.7% to 1.258 billion RMB; 3) 2023 revenue rebounded to 1.498 billion RMB (+19.1%); 4) 2024 revenue slightly decreased to 1.467 billion RMB (-2.1%) [4][5]. - The net profit turned positive in 2023 at 21.28 million RMB but turned into a significant loss of 589 million RMB in 2024, primarily due to goodwill impairment related to a previous acquisition [5] [11]. Core Business Decline - The main reason for the negative revenue growth is the drastic decline in the traditional core business of "information and appointment services," which fell by 19.3% from 1.151 billion RMB in 2023 to 929 million RMB in 2024, now accounting for only 63.4% of total revenue [6][11]. - This core business, which previously constituted 100% of revenue in 2020, has been severely impacted by competition from emerging platforms like Douyin and Xiaohongshu, which have diverted advertising budgets from medical beauty institutions [6][11]. New Business Development - In response to the pressure on traditional business, the company launched the "Brand Aesthetic Center" in 2023, generating revenue of 13 million RMB, which grew to 169 million RMB in 2024 [7][11]. - Despite rapid revenue growth in the light medical beauty chain business, its profitability remains weak, with gross margins of only 22.26% in 2024 and further declining to 18.78% in Q1 2025 [8][11]. Cost and Operational Challenges - The operational costs of the light medical beauty chain business have surged, with costs rising from 9.6 million RMB in 2023 to 132 million RMB in 2024, representing 77.7% of revenue [8][10]. - The company faces challenges in managing the operational efficiency of its new business model, which differs significantly from its traditional medical beauty operations [11].